Articles tagged with Vaccine Development
A new rapid viral plaque detection system enabled by holography and deep learning can help accelerate vaccine and drug development. The system reduces the detection time of traditional viral plaque assays by up to 48 hours, eliminating chemical staining and manual counting.
The study developed multi-valent mRNA vaccines targeting monkeypox enveloped or mature viron surface antigens, inducing dynamic immune responses with robust IgG and neutralizing activities. The vaccines protected a mouse model from lethal VACV challenge.
A German federal funding program will support a five-year research collaboration to develop specialty lipids and auxiliaries for mRNA vaccines. The project aims to enhance production capacities and improve the resilience of supply chains for future mRNA therapeutics.
Scientists at UCSF and NIBSC have developed two new oral polio vaccines with genetically engineered weakened poliovirus to reduce reversion to dangerous forms. These vaccines aim to boost the World Health Organization's efforts to eradicate polio, which has persisted despite successful international vaccination campaigns.
CHOP researchers have developed stable, universal MHC-I molecules that can be produced rapidly at scale, allowing for the development of effective and universal immunotherapies. These engineered MHC-I molecules promote peptide exchange across multiple HLA allotypes, covering various forms.
Researchers at Karolinska Institutet have developed a new method called single-particle profiling (SPP) to study bioparticles in health and disease. The SPP enables the measurement of thousands of particles between 5 and 200 nanometres in size, with potential applications in vaccine development and creating more effective nanocarriers.
A study of 17,000 people across eight African countries found a decline in vaccine confidence, particularly for COVID-19 vaccines. The drop in routine childhood vaccinations has led to six million fewer children receiving life-saving shots, putting decades of progress at risk.
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.
Nebraska scientists have made significant progress in developing a safe and effective long-lasting swine flu vaccine. The Epigraph algorithm enables the creation of a universal flu vaccine that protects against multiple types of influenza viruses for at least one year and is suitable for all age groups.
A Johns Hopkins Medicine-led team identified protein fragments that stimulate the immune system to recognize and attack HIV. The study's technique, called reductionist cell-free antigen processing, replicates the complex events in the human immune system, enabling the identification of immunodominant epitopes.
Researchers found that boosting vaccine use can reduce lockdown intensity and duration, but the relationship varies based on factors like disease severity and vaccination speed. The study suggests a nuanced approach to balancing lockdowns and vaccinations in future pandemics.
A nationwide study of nearly 10,000 adults identifies 12 hallmarks of long COVID, including debilitating fatigue, loss of smell or taste, and gastrointestinal symptoms. The findings provide a new scoring system for clinicians to define and investigate treatments for patients with long COVID.
Researchers at UNC School of Medicine discovered that human T cells can independently control RSV replication in lung tissue, suggesting a new approach to developing vaccines. The study's findings support the development of RSV vaccines that elicit effective T cell responses to improve vaccine efficacy.
The study, published in Science Translational Medicine, shows robust T-cell responses in volunteers participating in a phase 1 clinical trial of a self-assembling nanoparticle HIV vaccine. The antigen used stimulates VRC01-class B cells, an immune response considered promising for boosting in further studies.
Research reveals that age-dependent changes in germinal centres lead to reduced vaccine response in older people. The study demonstrates that reversing these changes can be achieved through interventions.
A new study investigates lockdowns and vaccines' complementary or substitutive roles in mitigating COVID-19's effects. The researchers found that vaccinations should be relaxed after substantial vaccination rates, but vastly different policies may be optimal depending on parameters.
A clinical trial has started enrolling volunteers to test the experimental H1ssF-3928 mRNA-LNP vaccine, developed by NIAID's Vaccine Research Center, for its safety and ability to induce an immune response. The trial aims to find an optimal dosage and compare it with a current seasonal flu vaccine.
A recent study by Monash University researchers found that a unique subtype of an immune cell produces long-lasting antibodies in response to certain vaccinations. This discovery may lead to the development of improved vaccines providing life-long protection.
Researchers found that Fiocruz's partnership with AstraZeneca was crucial to the success of COVID-19 vaccine production in Brazil. The partnership demonstrated the importance of technology transfer agreements, regulatory support, and political skill. Bio-Manguinhos facility played a significant role in producing vaccines, making over 5...
Researchers at the University of Missouri identified occludin protein as a mediator for cell-to-cell transmission of coronavirus. The study found that damaged occludin protein enables virus replication and spread to neighboring cells, worsening symptoms.
The International Vaccine Institute (IVI) has started clinical development of DuoChol, a new oral cholera vaccine in capsule form. This innovation offers improved thermostability, reducing storage challenges, while making vaccines more accessible to those who need them most.
The University of Liverpool is conducting a Phase I trial of a new Zika virus vaccine designed for pregnant women, which has shown promising results in animal studies. The vaccine aims to generate highly protective and long-lasting immunity against the mosquito-borne virus that can cause severe foetal birth defects.
A world-leading international trial has found that the BCG vaccine does not protect healthcare workers against COVID-19, despite boosting 'front-line' immunity in infants and protecting against respiratory infections. The research involved 3988 healthcare workers and showed a higher risk of symptomatic COVID-19 in the BCG group.
The NIH is conducting a clinical trial to evaluate the JYNNEOS mpox vaccine's safety and immune response in adolescents aged 12-17. The trial, launched at George Washington University, aims to determine if the vaccine can protect teens from this painful and sometimes deadly disease.
A new vaccine type, mRNA-4157/V940, added to immunotherapy significantly reduced melanoma recurrence and death rates. The combination was found to be effective in 22.4% of patients compared to 40% without the vaccine.
The primary COVID-19 vaccines provided adequate protection against transmission, hospitalization, and death, but their effectiveness waned in the face of the Omicron variant. The study found that vaccines developed prior to Omicron's emergence were 83% effective against infection at baseline, but this decreased to 47% by 40 weeks.
Researchers recognize the need for improved COVID-19 vaccines to prevent transmission and infection. Mucosal vaccines targeting the respiratory tract could be effective in blocking SARS-CoV-2 transmission and reducing disease burden.
Scientists create B cell organoids to screen conjugate vaccine candidates, identifying antigen-specific antibodies with potential applications. The platform accelerates testing throughput, offering insights into the immune response to vaccines.
Researchers have developed an organoid-based method to assess the potency of glycoconjugate vaccines, speeding up the vaccine development process. This method uses tissue from a single mouse to create hundreds of immune organoids, allowing for the assessment of dozens or even hundreds of vaccine candidates in just four days.
A new study creates an experimental combo vaccine by adding a key protein from norovirus to a harmless strain of rotavirus, generating antibodies against both viruses. Mice produced neutralizing antibodies in response to the vaccine.
The funding will support the development of next-generation delivery technology for mRNA vaccines and CRISPR-based genome editing. This will enable broader application of messenger RNA therapeutics, including for various diseases and immunological properties of nanoparticles.
Researchers at the University of Chicago have found that adding small molecules called immunomodulators to vaccine adjuvants can regulate the body's response to vaccines, reducing negative side effects. The study increased antibody response in flu vaccine models and reduced inflammation in typhoid vaccine models.
A new live attenuated SARS-CoV-2 vaccine administered through the nose has shown better immunity than injected vaccines in hamster models, reducing transmissibility. The vaccine stimulates local immunity by activating antibody immunoglobulin A and memory T cells, providing early protection against COVID-19.
Scientists discovered that B cells play a crucial role in controlling tuberculosis (TB) infections by directing helper T cells, known as T follicular helper (Tfh)-like cells, to granuloma tissue in the lungs where they can activate macrophages. This finding holds promise for developing better treatments and vaccines for TB.
An international project aims to discover modifiable cellular and molecular pathways of the developing infant immune system to improve infant vaccine responsiveness and prevent respiratory disease. By analyzing infants' immune systems from birth to five years old, researchers hope to identify biomarkers that predict vaccine responsiven...
Researchers at La Jolla Institute for Immunology have developed a high-resolution view of the LCMV glycoprotein, revealing its structure and potential vulnerabilities. The breakthrough enables the development of an engineered antibody that can prevent LCMV disease, offering a new route to treatment.
Researchers have created two novel adjuvants that significantly enhance the immune response to vaccines. The new adjuvants target toll-like receptors and are designed to be tailored for every individual vaccine, potentially reducing side effects and increasing effectiveness.
A systematic review and meta-analysis found demographic characteristics, comorbidities, and severe COVID-19 increase the risk of long COVID. Vaccination is protective against developing long COVID sequelae.
The study found that vaccination significantly reduces the risk of long COVID, while factors such as being overweight, female, smoker, or over 40 increase the likelihood of developing the condition. Vaccination halves people's risk of developing long Covid
Researchers at the University of Maryland School of Medicine are using mRNA vaccine technology to combat various infectious diseases. A new clinical trial aims to test an mRNA-based vaccine against malaria, with hopes for a rapid adaptive response to virus evolution and the manufacture of combination vaccines.
A new subset of memory B cells, marked by the FcRL5 receptor protein, has been identified as a predictor of long-lived antibody responses to influenza vaccination. These effector memory B cells can be detected seven days after immunization and correlate with vaccine antibody responses months later.
The CoDe tool enables precise edits to genetic codes, making vaccines safer and more effective. It can also modulate gene expression in small sections, aiding vaccine design and basic research.
A global maternal Strep B vaccination program could avert over 200,000 cases and more than 31,000 deaths, as well as reduce disability in children. The study found that a one-dose vaccine program could cost $1.7 billion globally, while saving $385 million in healthcare costs.
A global study aims to better understand the burden of Human papillomavirus (HPV) among girls and women in low- and lower middle-income countries. The study will inform effective strategies to prevent infection and introduce HPV vaccine into national programs, protecting the health of girls and women and reducing rates of cervical cancer.
A Phase 1 clinical trial of AAHI's thermostable, freeze-dried single-vial ID93 + GLA-SE vaccine candidate showed higher levels of antibodies and favorable cellular immune responses compared to the two-vial presentation. The results represent significant progress in global efforts to combat TB.
A Phase 1 trial of a thermostable tuberculosis (TB) vaccine candidate found it to be safe and stimulated both antibodies and cellular responses. The vaccine, ID93+GLA-SE, was well-tolerated and produced higher levels of antibodies in recipients compared to a non-thermostable formulation.
A 21-person commission of public health experts calls for networked communities sharing accurate vaccine information to counter misinformation. The US has seen a surge in anti-vaccine activism, leading to vaccine hesitancy and increased illnesses.
A recent study found that public investment in critical research contributed significantly to the development of mRNA COVID-19 vaccines. The US government invested at least $337 million in research over 35 years, including basic science and vaccine development.
The US government invested at least $337 million in critical research leading to mRNA COVID-19 vaccines before the pandemic, and $31.6 billion during it. These public investments saved millions of lives and have potential to address future pandemics and treat other diseases.
A new approach to boosting protein production has been discovered, which could lead to the generation of a universal booster for protein production. The breakthrough centers on Exin21, a sequence that increases mRNA synthesis and stability and protein expression and secretion.
The NIH is conducting a clinical trial to assess the safety and efficacy of S-217622, an investigational antiviral drug, in hospitalized adults with COVID-19. The trial aims to determine if S-217622 can improve recovery times compared to a placebo.
A new Northwestern University study suggests that COVID-19 boosters may be less effective due to pre-existing antibodies from initial vaccinations. The study found that these antibodies can rapidly clear the booster from the body, limiting its efficacy. Increasing time between vaccinations is also beneficial for the immune response.
Despite over 100 years of TB vaccine research, only one vaccine has been widely used, and a second is urgently needed to combat the ongoing pandemic. Promising new candidates are now in phase 3 trials, including an adjuvanted subunit vaccine that demonstrated 50% protection against TB infection in a phase II trial.
The Cleveland Clinic has launched a phase 1b clinical trial to evaluate the safety and immune response of a preventive breast cancer vaccine in high-risk individuals who have undergone prophylactic mastectomy. The study aims to recruit 6-12 patients and is expected to be completed by the end of 2023.
The Access to Advanced Health Institute has received a $9.9 million award to develop an intranasal bivalent influenza RNA vaccine candidate based on its self-amplifying RNA platform that targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens.
A new NIH-developed vaccine, VSV-SUDV, has been shown to completely protect cynomolgus macaques against a lethal Sudan virus challenge. The vaccine, based on the Ebola VSV vaccine concept, demonstrates cross-protective immune responses and provides rapid protective immunity to Sudan virus.
Researchers developed a new way to increase vaccine potency by changing the structural location of antigens and adjuvants. This approach, called 'rational vaccinology,' allows for precise dosing and tailored presentation of vaccine components, leading to improved immune response and cancer cell targeting.
A new vaccine has shown efficacy in protecting against three common fungal pathogens responsible for fatal fungal infections. The experimental vaccine targets Aspergillus, Candida, and Pneumocystis, with broad, cross-protective antifungal immunity demonstrated in preclinical animal models.
Researchers developed a vaccine platform that uses nanoscopic particles to deliver antigens, which can stimulate immune responses. The platform showed promise in early trials with mice, with improved survival rates against influenza and HIV.
An experimental vaccine against Marburg virus demonstrated a good safety profile and induced strong, long-lasting immunity in a Phase 1 clinical trial. The vaccine candidate, cAd3-Marburg, induced an immune response in 95% of participants and maintained that response for over 48 weeks.